Chair of Neurology, Poznan University of Medical Sciences, Poland.
Department of Clinical Neuroimmunology, Chair of Neurology, Poznan University of Medical Sciences, Poland.
J Neurol Sci. 2017 Sep 15;380:22-26. doi: 10.1016/j.jns.2017.06.048. Epub 2017 Jun 30.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system characterized by a variable clinical course. Different pathogenic mechanisms responsible for relapsing remitting (RRMS) and primary progressive multiple sclerosis (PPMS) are modulated by immunological process with important role of chemokine network. CXCL10 and CXCL13 chemokines act as chemoattractants and modulators of proinflammatory reactions promoting process of demyelination. In the present study, we investigated the concentrations of CXCL10 and CXCL13 in serum and cerebrospinal fluid (CSF) of patients with RRMS and PPMS.
The study groups comprised 25 RRMS patients (39,5±12years), 24 PPMS patients (49,9±10,5years), 31 healthy individuals (36±10,4years) with tension headache without symptoms of inflammatory diseases. A quantitive test kit based on ELISA has been used for chemokines measurement. Correlations analysis between the levels of CXCL10, CXCL13 and patient age, duration of MS, EDSS and IgG index were done.
The mean concentration of CXCL10 in the CSF was statistically significantly higher in RRMS in comparison with the control group. The mean concentration of CXCL13 in the CSF was significantly higher in RRMS and PPMS than in the control group. The results have shown that in the stable phase of MS without relapse, mean concentration of CXCL10 and CXCL13 in CSF did not differ significantly between RRMS and PPMS. In PPMS a positive correlation between IgG index and CSF CXCL10 level or CSF CXCL13 level was observed. In RRMS a positive correlation between IgG index and CSF CXCL13 level was observed.
These data indicate involvement of CXCL10 and CXCL13 chemokines in immunopathogenetic mechanisms in MS. There was no significant difference between mean CXCL10 or CXCL13 concentrations in the CSF in both RRMS and PPMS patients. No significant correlations were found between patient age and chemokines levels in theCSF in all groups. It suggest that these chemokines play similar role in inflammatory process despite more pronounced neurodegenerative process in PPMS.
多发性硬化症（MS）是一种中枢神经系统的慢性炎症性脱髓鞘疾病，其临床过程多变。导致复发缓解型多发性硬化症（RRMS）和原发性进展型多发性硬化症（PPMS）的不同发病机制受免疫过程调节，趋化因子网络起着重要作用。趋化因子 CXCL10 和 CXCL13 作为趋化因子和促炎反应的调节剂，促进脱髓鞘过程。在本研究中，我们研究了 RRMS 和 PPMS 患者血清和脑脊液（CSF）中 CXCL10 和 CXCL13 的浓度。
研究组包括 25 例 RRMS 患者（39.5±12 岁）、24 例 PPMS 患者（49.9±10.5 岁）和 31 名健康个体（36±10.4 岁），他们患有紧张性头痛且无炎症性疾病症状。使用基于 ELISA 的定量试剂盒测量趋化因子。对 CXCL10、CXCL13 水平与患者年龄、MS 病程、EDSS 和 IgG 指数之间的相关性进行分析。
RRMS 患者 CSF 中 CXCL10 的平均浓度明显高于对照组。RRMS 和 PPMS 患者 CSF 中 CXCL13 的平均浓度明显高于对照组。结果表明，在无复发的 MS 稳定期，RRMS 和 PPMS 患者 CSF 中 CXCL10 和 CXCL13 的平均浓度无显著差异。在 PPMS 中，IgG 指数与 CSF CXCL10 水平或 CSF CXCL13 水平呈正相关。在 RRMS 中，IgG 指数与 CSF CXCL13 水平呈正相关。
这些数据表明趋化因子 CXCL10 和 CXCL13 参与了 MS 的免疫发病机制。RRMS 和 PPMS 患者 CSF 中 CXCL10 或 CXCL13 的平均浓度无显著差异。在所有组中，患者年龄与 CSF 中趋化因子水平之间均未发现显著相关性。这表明这些趋化因子在炎症过程中发挥相似的作用，尽管 PPMS 中更明显的神经退行性过程。
